NEO Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

8.370

Open

8.200

VWAP

8.19

Vol

1.94M

Mkt Cap

1.07B

Low

7.965

Amount

15.85M

EV/EBITDA(TTM)

727.19

Total Shares

130.14M

EV

1.27B

EV/OCF(TTM)

242.63

P/S(TTM)

1.47

NeoGenomics, Inc. is a cancer diagnostics company specializing in cancer genetics testing and information services. The Company offers comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with diagnostic and predictive testing to help them diagnose and treat cancer. Its services include clinical cancer testing; interpretation and consultative services; molecular and NGS testing; comprehensive technical and professional services offering; clinical trials and research; validation laboratory services, and oncology data solutions. It operates a network of laboratories for full-service sample processing and analysis services throughout the United States and a full-service sample-processing laboratory in Cambridge, United Kingdom. Its testing services include Cytogenetics (karyotype analysis), Fluorescence In-Situ Hybridization (FISH), Flow cytometry, and others.

Show More

Events Timeline

(ET)

2026-03-16

09:00:00

Stock Futures Rise as Markets Seek Recovery

2026-02-17 (ET)

2026-02-17

16:40:00

Major U.S. Averages End Broadly Higher, Nasdaq Up 0.14%

2026-02-17

12:00:00

Major Averages Mixed as Tech Stocks Face Pressure

2026-02-17

07:50:00

Company Sees FY26 Revenue of $793M to $801M

2026-02-17

07:40:00

NeoGenomics Q4 Revenue $190.17M Beats Expectations

2026-01-12 (ET)

2026-01-12

07:40:00

NeoGenomics Announces CFO Succession Plan

2026-01-12

07:40:00

NeoGenomics Reports Preliminary FY25 Revenue of $727M

News

Newsfilter

04-13Newsfilter

NeoGenomics to Present New Research at AACR Annual Meeting

Newsfilter

04-07Newsfilter

NeoGenomics to Report Q1 2026 Financial Results on April 28

Globenewswire

03-23Globenewswire

U.S. Launches $12 Billion Strategic Minerals Reserve Initiative

Newsfilter

03-16Newsfilter

NeoGenomics Secures Medicare Coverage for PanTracer LBx Test

Newsfilter

02-25Newsfilter

NeoGenomics Launches RaDaR ST for Molecular Residual Disease Detection

seekingalpha

02-17seekingalpha

NeoGenomics Reports Record Q4 2025 Revenues of $190 Million

11 Analyst Rating

Wall Street analysts forecast NEO stock price to rise

5 Buy

6 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

12.00

Averages

14.00

High

16.00

Current: 0.000

Low

12.00

Averages

14.00

High

16.00

Piper Sandler

NULL -> Overweight

maintain

$12 -> $13

AI Analysis

2026-02-24

Reason

Piper Sandler

Price Target

$12 -> $13

AI Analysis

2026-02-24

maintain

NULL -> Overweight

Reason

Piper Sandler raised the firm's price target on NeoGenomics to $13 from $12 following quarterly results. The firm keeps an Overweight rating on the shares.

TD Cowen

Dan Brennan

Buy

maintain

$14 -> $16

2026-01-07

Reason

TD Cowen

Dan Brennan

Price Target

$14 -> $16

2026-01-07

maintain

Buy

Reason

TD Cowen analyst Dan Brennan raised the firm's price target on NeoGenomics to $16 from $14 and keeps a Buy rating on the shares. The firm adjusted targets in the diagnostics group as part of a Q4 preview. It expects solid results and 2026 outlooks for the sector, saying strong fundamentals remain.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for NEO

Unlock Now

Valuation Metrics

The current forward P/E ratio for Neogenomics Inc (NEO.O) is 222.22, compared to its 5-year average forward P/E of 28.03. For a more detailed relative valuation and DCF analysis to assess Neogenomics Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

28.03

Current PE

222.22

Overvalued PE

163.29

Undervalued PE

-107.22

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

N/A

5Y Average EV/EBITDA

256.13

Current EV/EBITDA

134.67

Overvalued EV/EBITDA

1373.66

Undervalued EV/EBITDA

-861.40

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

5Y Average PS

3.67

Current PS

1.24

Overvalued PS

6.42

Undervalued PS

0.93

Financials

AI Analysis

Annual

Quarterly

Whales Holding NEO

Greenhouse Funds LLLP

American Capital Management, Inc.

Trading Trends

People Also Watch

Frequently Asked Questions

What is Neogenomics Inc (NEO) stock price today?

The current price of NEO is 8.23 USD — it has decreased -1.44

What is Neogenomics Inc (NEO)'s business?

NeoGenomics, Inc. is a cancer diagnostics company specializing in cancer genetics testing and information services. The Company offers comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with diagnostic and predictive testing to help them diagnose and treat cancer. Its services include clinical cancer testing; interpretation and consultative services; molecular and NGS testing; comprehensive technical and professional services offering; clinical trials and research; validation laboratory services, and oncology data solutions. It operates a network of laboratories for full-service sample processing and analysis services throughout the United States and a full-service sample-processing laboratory in Cambridge, United Kingdom. Its testing services include Cytogenetics (karyotype analysis), Fluorescence In-Situ Hybridization (FISH), Flow cytometry, and others.

What is the price predicton of NEO Stock?

Wall Street analysts forecast NEO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NEO is14.00 USD with a low forecast of 12.00 USD and a high forecast of 16.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Neogenomics Inc (NEO)'s revenue for the last quarter?

Neogenomics Inc revenue for the last quarter amounts to 190.17M USD, increased 10.56

What is Neogenomics Inc (NEO)'s earnings per share (EPS) for the last quarter?

Neogenomics Inc. EPS for the last quarter amounts to -0.08 USD, decreased -33.33

How many employees does Neogenomics Inc (NEO). have?

Neogenomics Inc (NEO) has 2500 emplpoyees as of April 21 2026.

What is Neogenomics Inc (NEO) market cap?

Today NEO has the market capitalization of 1.07B USD.